Tissue Eng Regen Med.  2022 Apr;19(2):237-252. 10.1007/s13770-022-00430-y.

Nanozyme-Based Enhanced Cancer Immunotherapy

• Phan NM
• Nguyen TL
• Kim J

• KMID: 2528121
• DOI: http://doi.org/10.1007/s13770-022-00430-y

Abstract

Catalytic nanoparticles with natural enzyme-mimicking properties, known as nanozymes, have emerged as excellent candidate materials for cancer immunotherapy. Owing to their enzymatic activities, artificial nanozymes not only serve as responsive carriers to load drugs and therapeutic molecules for cancer treatment, but also act as enzymes for modulating the immunosuppression of the tumor microenvironment (TME) via the catalytic activities of catalase, peroxidase, superoxide dismutase, and oxidase. The immunosuppressive pro-tumor TME can be reversed to the immunoactive anti-tumor TME by utilizing both reactive oxygen species (ROS)-generating and ROS-scavenging nanozymes, which enhance the efficacy of cancer immunotherapy. In this review, we introduce representative ROS-generating and ROSscavenging nanozymes and discuss how artificial nanozymes respond to the conditions of the TME. Based on the mutual interaction between nanozymes and TME, recent therapeutic pathways to provoke anti-cancer immune responses using nanozymes are discussed.

Keyword

Cancer immunotherapy; Nanozymes; Reactive oxygen species; Tumor microenvironment; Immunogenic cell death